NantKwest to Present Data on the First next Generation GMP-Grade NK Cell Line for Combination Immunotherapy with Rituximab, Trastuzumab, and Daratumumab at Upcoming AACR Cancer Conference

Positive Preclinical Data Of The First “Off The Shelf,” GMP-Grade, IL-2-Independent NK Cell Line Expressing The High-Affinity Fc-Receptor To Augment Antibody Therapeutics

CULVER CITY, Calif. – April 15, 2016 - NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases, today announced that the company will be presenting an abstract at the upcoming American Association of Cancer Research Annual Meeting (AACR).